{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:00:55Z","timestamp":1793300455038,"version":"4.5.0"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>\n                    <jats:italic>Helicobacter pylori (H. pylori)<\/jats:italic>\n                    is a globally prevalent pathogen associated with a spectrum of gastrointestinal diseases, including chronic gastritis, peptic ulcer disease, and gastric malignancies. Although clarithromycin-based triple therapy continues to be effective in certain geographic areas, increasing global resistance highlights the need for treatment approaches tailored to local antibiotic susceptibility patterns. Recent clinical trials have shifted toward optimized quadruple regimens, particularly bismuth- and vonoprazan-based therapies, and resistance-guided treatment. Novel agents such as Rifasutenizol (TNP-2198) are entering phase 3 evaluation and show activity against multidrug-resistant strains. Adjunctive and alternative strategies including probiotics, phytochemicals, phage-derived enzymes, and nanoparticle-based delivery demonstrate synergistic effects in improving eradication and reducing antibiotic-associated adverse events. Multi-strain probiotic formulations and plant-derived compounds such as curcumin, catechins, and quercetin consistently suppress\n                    <jats:italic>H. pylori<\/jats:italic>\n                    virulence pathways and gastric inflammation in clinical and preclinical studies. This review provides an overview of current evidence from clinical trials and emerging therapeutic innovations, emphasizing balanced integration of conventional and next-generation approaches for sustainable global\n                    <jats:italic>H. pylori<\/jats:italic>\n                    management.\n                  <\/jats:p>","DOI":"10.3389\/fmicb.2025.1652943","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:40:02Z","timestamp":1764744002000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Therapeutic advances and future directions in Helicobacter pylori eradication"],"prefix":"10.3389","volume":"16","author":[{"given":"Vidya","family":"Suresh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amritavarshini","family":"Sreekumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shine","family":"Sadasivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalitha","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2217\/fvl.13.58","article-title":"Isolation and characterization of bacteriophages of Helicobacter pylori isolated from Egypt.","volume":"8","author":"Abdel-Haliem","year":"2013","journal-title":"Future Virol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/antibiotics10020124","article-title":"Phage-Encoded endolysins.","volume":"10","author":"Abdelrahman","year":"2021","journal-title":"Antibiotics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e70432","DOI":"10.1002\/hsr2.70432","article-title":"First-Line levofloxacin-based triple therapy versus standard bismuth-based quadruple therapy for Helicobacter pylori eradication in Saudi Arabia: A retrospective single-center study.","volume":"8","author":"Abdulqader","year":"2025","journal-title":"Health Sci. Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e00470","DOI":"10.1016\/j.btre.2020.e00470","article-title":"Plants against Helicobacter pylori to combat resistance: An ethnopharmacological review.","volume":"26","author":"Abou Baker","year":"2020","journal-title":"Biotechnol. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3390\/metabo13010136","article-title":"Anti-Heliobacter pylori and anti-inflammatory potential of Salvia officinalis metabolites: In vitro and in silico studies.","volume":"13","author":"Alomar","year":"2023","journal-title":"Metabolites"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.3390\/plants11192617","article-title":"GC-MS profiling, Anti-Helicobacter pylori, and anti-inflammatory activities of three apiaceous fruits\u2019. Essential Oils.","volume":"11","author":"Alomar","year":"2022","journal-title":"Plants"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.3390\/life13071512","article-title":"Anti- Helicobacter pylori, antioxidant, antidiabetic, and anti-alzheimer\u2019s activities of laurel leaf extract treated by moist heat and molecular docking of its flavonoid constituent, naringenin, against acetylcholinesterase and butyrylcholinesterase.","volume":"13","author":"Al-Rajhi","year":"","journal-title":"Life"},{"key":"B8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3390\/jfb14040237","article-title":"Pharmacological evaluation of acacia nilotica flower extract against Helicobacter pylori and human hepatocellular carcinoma in vitro and in silico.","volume":"14","author":"Al-Rajhi","year":"","journal-title":"J. Funct. Biomater."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.3390\/molecules30173520","article-title":"Phytochemical characterization and Anti- Helicobacter pylori potential of Haloxylon articulatum extracts: Antioxidant activity and molecular docking insights.","volume":"30","author":"Al-Rashidi","year":"2025","journal-title":"Molecules"},{"key":"B10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jep.2012.11.033","article-title":"In vitro anti-Helicobacter pylori activity of a flavonoid rich extract of Glycyrrhiza glabra and its probable mechanisms of action.","volume":"145","author":"Asha","year":"2013","journal-title":"J. Ethnopharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"7965","DOI":"10.3390\/molecules27227965","article-title":"Valorization of Pimenta racemosa essential oils and extracts: gc-ms and LC-MS phytochemical profiling and evaluation of Helicobacter pylori inhibitory activity.","volume":"27","author":"Ayoub","year":"2022","journal-title":"Molecules"},{"key":"B12","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s00203-022-03314-w","article-title":"The impacts of probiotics in eradication therapy of Helicobacter pylori.","volume":"204","author":"Bai","year":"2022","journal-title":"Arch. Microbiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1007\/s12649-024-02490-8","article-title":"Impact of moist heat on phytochemical constituents, anti-Helicobacter pylori, antioxidant, anti-diabetic, hemolytic and healing properties of rosemary plant extract in vitro.","volume":"15","author":"Bakri","year":"2024","journal-title":"Waste Biomass Valorizat."},{"key":"B14","first-page":"1299","article-title":"Antibacterial activities of oxyprenylated chalcones and napthtoquinone against Helicobacter pylori.","volume":"9","author":"Bodet","year":"2014","journal-title":"Nat. Prod. Commun."},{"key":"B15","doi-asserted-by":"publisher","first-page":"6078","DOI":"10.3390\/molecules26196078","article-title":"Revisiting therapeutic strategies for h. pylori treatment in the context of antibiotic resistance: Focus on alternative and complementary therapies.","volume":"26","author":"Cardos","year":"2021","journal-title":"Molecules"},{"key":"B16","doi-asserted-by":"publisher","first-page":"116981","DOI":"10.1016\/j.jep.2023.116981","article-title":"In vitro anti-bactrical activity and its preliminary mechanism of action of the non-medicinal parts of Sanguisorba officinalis L. against Helicobacter pylori infection.","volume":"318","author":"Chen","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: Randomized clinical trial.","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.12998\/wjcc.v10.i19.6349","article-title":"Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea.","volume":"10","author":"Cho","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e088788","DOI":"10.1136\/bmjopen-2024-088788","article-title":"Efficacy of susceptibility-guided quadruple therapy with antibiotic resistance using the string test coupled with quantitative PCR for Helicobacter pylori eradication: A protocol of a multicentre, open, randomised clinical trial.","volume":"14","author":"Cui","year":"2024","journal-title":"BMJ Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e111030","DOI":"10.1371\/journal.pone.0111030","article-title":"The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: A meta-analysis.","volume":"9","author":"Dang","year":"2014","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3390\/medicina57070733","article-title":"Limosilactobacillus reuteri strains as adjuvants in the management of Helicobacter pylori infection.","volume":"57","author":"Dargenio","year":"2021","journal-title":"Medicina"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1360852","DOI":"10.3389\/fcimb.2024.1360852","article-title":"The effects and mechanisms of natural products on Helicobacter pylori eradication.","volume":"14","author":"Deng","year":"2024","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e13121","DOI":"10.1111\/hel.13121","article-title":"Tetracycline three times daily versus four times daily in bismuth-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection: A multicenter, noninferiority, randomized controlled trial.","volume":"29","author":"Ding","year":"2024","journal-title":"Helicobacter"},{"key":"B24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jep.2009.03.030","article-title":"In vitro and in vivo anti-Helicobacter pylori activity of Calophyllum brasiliense Camb.","volume":"123","author":"do Carmo Souza","year":"2009","journal-title":"J. Ethnopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5114\/pg.2024.139426","article-title":"Vonoprazan a novel potassium competitive acid blocker; another leap forward.","volume":"19","author":"Elsabaawy","year":"2024","journal-title":"Prz. Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1355460","DOI":"10.3389\/fmicb.2024.1355460","article-title":"In vitro anti-Helicobacter pylori activity and the underlining mechanism of an empirical herbal formula\u2013Hezi Qingyou.","volume":"15","author":"Feng","year":"2024","journal-title":"Front. Microbiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"105429","DOI":"10.1016\/j.micinf.2024.105429","article-title":"Screening and in silico characterization of prophages in Helicobacter pylori clinical strains.","volume":"27","author":"Ferreira","year":"2025","journal-title":"Microbes Infect."},{"key":"B28","doi-asserted-by":"publisher","first-page":"7885","DOI":"10.3390\/ijms23147885","article-title":"Characterization and genomic analysis of a new phage infecting Helicobacter pylori.","volume":"23","author":"Ferreira","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1016\/j.vaccine.2018.07.033","article-title":"Immunization with a recombinant fusion protein protects mice against Helicobacter pylori infection.","volume":"36","author":"Ghasemi","year":"2018","journal-title":"Vaccine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/pathogens10010015","article-title":"Rifabutin for the treatment of Helicobacter pylori infection: A review.","volume":"10","author":"Gisbert","year":"2020","journal-title":"Pathogens"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00253-017-8535-7","article-title":"Helicobacter pylori treatment: Antibiotics or probiotics.","volume":"102","author":"Goderska","year":"2018","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"795","DOI":"10.7326\/M19-3734","article-title":"Rifabutin-Based triple therapy (RHB-105) for Helicobacter pylori eradication: A double-blind, randomized, controlled trial.","volume":"172","author":"Graham","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/LLKF7871","article-title":"Eradication of Helicobacter pylori for prevention of aspirin-associated peptic ulcer bleeding in adults over 65 years: The HEAT RCT.","volume":"29","author":"Hawkey","year":"2022","journal-title":"Health Technol. Assess."},{"key":"B34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","article-title":"Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis.","volume":"153","author":"Hooi","year":"2017","journal-title":"Gastroenterology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"12954","DOI":"10.3748\/wjg.v21.i45.12954","article-title":"Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis.","volume":"21","author":"Hsu","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"100975","DOI":"10.1016\/j.lanmic.2024.100975","article-title":"Effects of amoxicillin dosage on cure rate, gut microbiota, and antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: A multicentre, open-label, non-inferiority randomised controlled trial.","volume":"6","author":"Hu","year":"2025","journal-title":"Lancet Microbe"},{"key":"B37","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fcimb.2017.00168","article-title":"Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance.","volume":"7","author":"Hu","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"106805","DOI":"10.1016\/j.fitote.2025.106805","article-title":"GC\u2013MS-driven network pharmacology analysis reveals the bacteriostatic potential of Amomum villosum lour. essential oil against Helicobacter pylori in vitro.","volume":"186","author":"Huang","year":"2025","journal-title":"Fitoterapia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1418129","DOI":"10.3389\/fmicb.2024.1418129","article-title":"Novel therapeutic regimens against Helicobacter pylori: An updated systematic review.","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Microbiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e13017","DOI":"10.1111\/hel.13017","article-title":"Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial.","volume":"28","author":"Ismail","year":"2023","journal-title":"Helicobacter"},{"key":"B41","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3390\/antibiotics9100685","article-title":"Rifabutin-Containing triple therapy (RHB-105) for eradication of Helicobacter pylori: Randomized ERADICATE Hp Trial.","volume":"9","author":"Kalfus","year":"2020","journal-title":"Antibiotics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e2302532","DOI":"10.1002\/smll.202302532","article-title":"Future nanotechnology-based strategies for improved management of Helicobacter pylori infection.","volume":"20","author":"Kamankesh","year":"2024","journal-title":"Small"},{"key":"B43","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10238-020-00643-2","article-title":"Evaluation of different proton pump inhibitors combined with bismuth quadruple regimens in Helicobacter pylori eradication.","volume":"20","author":"Kan","year":"2020","journal-title":"Clin. Exp. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/MCG.0000000000001719","article-title":"Helicobacter pylori world gastroenterology organization global guideline.","volume":"57","author":"Katelaris","year":"2023","journal-title":"J. Clin. Gastroenterol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"72","DOI":"10.23750\/abm.v89i8-S.7947","article-title":"Helicobacter pylori, transmission routes and recurrence of infection: State of the art.","volume":"89","author":"Kayali","year":"2018","journal-title":"Acta Biomed."},{"key":"B46","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12876-021-01977-1","article-title":"Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections.","volume":"21","author":"Keikha","year":"2021","journal-title":"BMC Gastroenterol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"21460","DOI":"10.1002\/jcp.28870","article-title":"Potential antigen candidates for subunit vaccine development against Helicobacter pylori infection.","volume":"234","author":"Keikha","year":"2019","journal-title":"J. Cell Physiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1245993","DOI":"10.3389\/fgstr.2023.1245993","article-title":"Efficacy and safety of Lacticaseibacillus rhamnosus R0011 and Lactobacillus helveticus R0052 as an adjuvant for Helicobacter pylori eradication: A double-blind, randomized, placebo-controlled study.","volume":"2","author":"Kiattiweerasak","year":"2023","journal-title":"Front. Gastroenterol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/antibiotics9080436","article-title":"Best Helicobacter pylori eradication strategy in the era of antibiotic resistance.","volume":"9","author":"Kim","year":"2020","journal-title":"Antibiotics"},{"key":"B50","doi-asserted-by":"publisher","first-page":"140","DOI":"10.17116\/terarkh20168812140-148","article-title":"[Use of probiotics and probiotic-based immunomodulators as adjuvant therapy for Helicobacter pylori eradication].","volume":"88","author":"Konorev","year":"2016","journal-title":"Ter Arkh"},{"key":"B51","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1470-2045(08)70072-X","article-title":"Screening for gastric cancer in Asia: Current evidence and practice.","volume":"9","author":"Leung","year":"2008","journal-title":"Lancet Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"16318","DOI":"10.1038\/s41598-025-01117-9","article-title":"Randomized multicenter trial comparing minocycline and ornidazole with classical quadruple therapy in Helicobacter pylori treatment.","volume":"15","author":"Lin","year":"2025","journal-title":"Sci. Rep."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e13094","DOI":"10.1111\/hel.13094","article-title":"Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: Systematic review and meta-analyses of randomized controlled trials.","volume":"29","author":"Liu","year":"2024","journal-title":"Helicobacter"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1330029","DOI":"10.3389\/fmicb.2023.1330029","article-title":"Helicobacter pylori infection in humans and phytotherapy, probiotics, and emerging therapeutic interventions: A review.","volume":"14","author":"Liu","year":"2024","journal-title":"Front. Microbiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e70229","DOI":"10.1002\/ctm2.70229","article-title":"Large-scale cluster randomised trial reveals effectiveness of Helicobacter pylori eradication for gastric cancer prevention.","volume":"15","author":"Liu","year":"2025","journal-title":"Clin. Trans. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jncc.2024.06.006","article-title":"Helicobacter pylori eradication for primary prevention of gastric cancer: Progresses and challenges.","volume":"4","author":"Liu","year":"2024","journal-title":"J. Natl. Cancer Center"},{"key":"B57","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.colsurfb.2018.01.008","article-title":"Construction and optimization of pH-sensitive nanoparticle delivery system containing PLGA and UCCs-2 for targeted treatment of Helicobacter pylori.","volume":"164","author":"Luo","year":"2018","journal-title":"Colloids Surfaces B: Biointerfaces"},{"key":"B58","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the maastricht v\/florence consensus report.","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/ueg2.12605","article-title":"Quadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countries.","volume":"12","author":"Medel-Jara","year":"2024","journal-title":"U. Eur. Gastroenterol. J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3390\/children9060795","article-title":"The challenges of eradicating pediatric Helicobacter pylori infection in the era of probiotics.","volume":"9","author":"Meli\u0163","year":"2022","journal-title":"Children"},{"key":"B61","doi-asserted-by":"publisher","first-page":"5964","DOI":"10.3390\/ijms24065964","article-title":"Chalcones and gastrointestinal cancers: Experimental evidence.","volume":"24","author":"Michalkova","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.3390\/jcm10163473","article-title":"Clinical relevance of Helicobacter pylori infection.","volume":"10","author":"Mladenova","year":"2021","journal-title":"J. Clin. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","article-title":"Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: A phase III, randomised, double-blind study.","volume":"65","author":"Murakami","year":"2016","journal-title":"Gut"},{"key":"B64","doi-asserted-by":"publisher","first-page":"11708","DOI":"10.3390\/ijms241411708","article-title":"Antibiotic resistance, susceptibility testing and stewardship in Helicobacter pylori infection.","volume":"24","author":"Ng","year":"2023","journal-title":"Intern. J. Mol. Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3390\/antibiotics13020136","article-title":"Sequential versus standard triple therapy for first-line Helicobacter pylori eradication: An update.","volume":"13","author":"Nyssen","year":"2024","journal-title":"Antibiotics"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.3390\/jcm11061658","article-title":"Experience with rifabutin-containing therapy in 500 patients from the European registry on Helicobacter pylori management (Hp-EuReg).","volume":"11","author":"Nyssen","year":"2022","journal-title":"J. Clin. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/diseases9040066","article-title":"Overview of Helicobacter pylori infection: Clinical features, treatment, and nutritional aspects.","volume":"9","author":"\u00d6ztekin","year":"2021","journal-title":"Diseases"},{"key":"B68","doi-asserted-by":"publisher","first-page":"13842","DOI":"10.3748\/wjg.v20.i38.13842","article-title":"Gastric cancer: Prevention, screening and early diagnosis.","volume":"20","author":"Pasechnikov","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1572-0241.2001.03452.x","article-title":"Randomized study of two \u201crescue\u201d therapies for Helicobacter pylori-infected patients after failure of standard triple therapies.","volume":"96","author":"Perri","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/hel.12041","article-title":"Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy.","volume":"18","author":"Prasertpetmanee","year":"2013","journal-title":"Helicobacter"},{"key":"B71","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13765-023-00832-z","article-title":"Inhibitory potential of rutin and rutin nano-crystals against Helicobacter pylori, colon cancer, hemolysis and Butyrylcholinesterase in vitro and in silico.","volume":"66","author":"Qanash","year":"2023","journal-title":"Appl. Biol. Chem."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e13118","DOI":"10.1111\/hel.13118","article-title":"Vonoprazan\u2013Amoxicillin dual therapy with different amoxicillin administration regimens for Helicobacter pylori treatment: A randomized controlled trial.","volume":"29","author":"Qiu","year":"2024","journal-title":"Helicobacter"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3390\/microorganisms11051312","article-title":"Helicobacter pylori and its role in gastric Cancer.","volume":"11","author":"Reyes","year":"2023","journal-title":"Microorganisms"},{"key":"B74","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.3748\/wjg.v31.i10.102289","article-title":"Overcoming antibiotic-resistant Helicobacter pylori infection: Current challenges and emerging approaches.","volume":"31","author":"Rocha","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"787","DOI":"10.14309\/ajg.0000000000003084","article-title":"Comparative efficacy and safety of potassium-competitive acid blocker (P-CAB) based dual, triple and quadruple regimens for first line H. pylori infection treatment: A systematic review and network meta-analysis.","volume":"120","author":"Rokkas","year":"2025","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3390\/ijms19082361","article-title":"Phytochemicals in Helicobacter pylori infections: What are we doing now?","volume":"19","author":"Salehi","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4103\/1319-3767.54743","article-title":"Helicobacter pylori infection in developing countries: The burden for how long?","volume":"15","author":"Salih","year":"2009","journal-title":"Saudi J. Gastroenterol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"105594","DOI":"10.1016\/j.micpath.2022.105594","article-title":"A new approach against Helicobacter pylori using plants and its constituents: A review study.","volume":"168","author":"Sathianarayanan","year":"2022","journal-title":"Microb. Pathog"},{"key":"B79","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3390\/pathogens13050392","article-title":"Helicobacter pylori outer membrane proteins and virulence factors: Potential targets for novel therapies and vaccines.","volume":"13","author":"Sedarat","year":"2024","journal-title":"Pathogens"},{"key":"B80","doi-asserted-by":"publisher","first-page":"15989","DOI":"10.1038\/s41598-025-98606-8","article-title":"Vonoprazan-based therapy versus standard regimen for Helicobacter pylori infection management in Egypt: An open-label randomized controlled trial.","volume":"15","author":"Shekeban","year":"2025","journal-title":"Sci. Rep."},{"key":"B81","doi-asserted-by":"publisher","first-page":"17562848231192750","DOI":"10.1177\/17562848231192750","article-title":"Update on the second-line treatment of Helicobacter pylori infection: A narrative review.","volume":"16","author":"Shih","year":"2023","journal-title":"Therap. Adv. Gastroenterol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"101470","DOI":"10.1016\/j.jcmgh.2025.101470","article-title":"Decoding the ability of Helicobacter pylori to evade immune recognition and cause disease.","volume":"19","author":"Sirit","year":"2025","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.3748\/wjg.v22.i19.4766","article-title":"Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: A systematic review and meta-analysis.","volume":"22","author":"Song","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00438-4","article-title":"Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): A phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial.","author":"Song","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"B85","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/1040841X.2021.1975643","article-title":"Helicobacter pylori infection: From standard to alternative treatment strategies.","volume":"48","author":"Sousa","year":"2022","journal-title":"Crit. Rev. Microbiol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/jgh.14456","article-title":"Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.","volume":"34","author":"Sue","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"7295","DOI":"10.1016\/j.vaccine.2018.01.001","article-title":"Status of vaccine research and development for Helicobacter pylori.","volume":"37","author":"Sutton","year":"2019","journal-title":"Vaccine"},{"key":"B88","doi-asserted-by":"publisher","first-page":"116618","DOI":"10.1016\/j.jep.2023.116618","article-title":"Coptisine inhibits Helicobacter pylori and reduces the expression of CagA to alleviate host inflammation in vitro and in vivo.","volume":"314","author":"Tang","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"17600","DOI":"10.1073\/pnas.1418230111","article-title":"In vivo treatment of Helicobacter pylori infection with liposomal linolenic acid reduces colonization and ameliorates inflammation.","volume":"111","author":"Thamphiwatana","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B90","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1750-9378-9-43","article-title":"Inhibitory effect of piperine on Helicobacter pylori growth and adhesion to gastric adenocarcinoma cells.","volume":"9","author":"Tharmalingam","year":"2014","journal-title":"Infect. Agent Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1500921","DOI":"10.3389\/fimmu.2024.1500921","article-title":"Helicobacter pylori-targeted AI-driven vaccines: A paradigm shift in gastric cancer prevention.","volume":"15","author":"Tu","year":"2024","journal-title":"Front. Immunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/medicines5030093","article-title":"Flavonoids and other phenolic compounds from medicinal plants for pharmaceutical and medical aspects: An overview.","volume":"5","author":"Tungmunnithum","year":"2018","journal-title":"Medicines"},{"key":"B93","doi-asserted-by":"publisher","first-page":"8986","DOI":"10.1038\/s41598-024-59621-3","article-title":"Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: A prospective randomized study (VQ-HP trial).","volume":"14","author":"Tungtrongchitr","year":"2024","journal-title":"Sci. Rep."},{"key":"B94","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jep.2006.06.001","article-title":"Flavonoids with anti-Helicobacter pylori activity from Cistus laurifolius leaves.","volume":"108","author":"Ust\u00fcn","year":"2006","journal-title":"J. Ethnopharmacol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000350719","article-title":"Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.","volume":"88","author":"Venerito","year":"2013","journal-title":"Digestion"},{"key":"B96","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3390\/nu14030632","article-title":"A four-probiotics regimen combined with a standard Helicobacter pylori-eradication treatment reduces side effects and increases eradication rates.","volume":"14","author":"Viazis","year":"2022","journal-title":"Nutrients"},{"key":"B97","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/antibiotics12010141","article-title":"In vitro antibacterial and wound healing activities evoked by silver nanoparticles synthesized through probiotic bacteria.","volume":"12","author":"Vijayakumar","year":"2023","journal-title":"Antibiotics"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e70033","DOI":"10.1111\/hel.70033","article-title":"Efficacy and safety of cefuroxime\u2013tetracycline-containing bismuth quadruple therapy for Helicobacter pylori eradication in penicillin-allergic patients: A multicenter randomized controlled trial.","volume":"30","author":"Wang","year":"2025","journal-title":"Helicobacter"},{"key":"B99","doi-asserted-by":"publisher","first-page":"10368","DOI":"10.3748\/wjg.v20.i30.10368","article-title":"Medicinal plant activity on Helicobacter pylori related diseases.","volume":"20","author":"Wang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1120789","DOI":"10.3389\/fcimb.2023.1120789","article-title":"Comparative effectiveness of different probiotics supplements for triple Helicobacter pylori eradication: A network meta-analysis.","volume":"13","author":"Wang","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"e0318937","DOI":"10.1371\/journal.pone.0318937","article-title":"Guideline-based bismuth quadruple therapy for Helicobacter pylori infection in China: A systematic review and network meta-analysis.","volume":"20","author":"Wei","year":"2025","journal-title":"PLoS One"},{"key":"B102","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cgh.2009.09.030","article-title":"Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection.","volume":"8","author":"Wu","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.3390\/polym14152994","article-title":"Molecular docking and efficacy of Aloe vera gel based on chitosan nanoparticles against Helicobacter pylori and its antioxidant and anti-inflammatory activities.","volume":"14","author":"Yahya","year":"2022","journal-title":"Polymers"},{"key":"B104","doi-asserted-by":"publisher","first-page":"102529","DOI":"10.1016\/j.eclinm.2024.102529","article-title":"10-Day versus 14-day bismuth quadruple therapy for first-line eradication of Helicobacter pylori infection: A randomised, open-label, non-inferiority trial.","volume":"70","author":"Yang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B105","doi-asserted-by":"publisher","first-page":"100863","DOI":"10.3748\/wjg.v31.i13.100863","article-title":"Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which\u2019s better?","volume":"31","author":"Yang","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12876-024-03524-0","article-title":"Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces boulardii supplements on eradication of Helicobacter pylori.","volume":"24","author":"Yu","year":"2024","journal-title":"BMC Gastroenterol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e70018","DOI":"10.1111\/hel.70018","article-title":"Is tailored bismuth quadruple therapies (With Clarithromycin or Furazolidone) based on fecal molecular susceptibility testing in first-line Helicobacter pylori eradication treatment more effective? a three-arm, multicenter randomized clinical trial.","volume":"30","author":"Yu","year":"2025","journal-title":"Helicobacter"},{"key":"B108","doi-asserted-by":"publisher","first-page":"107600","DOI":"10.1016\/j.ijantimicag.2025.107600","article-title":"The impact of probiotics on Helicobacter pylori eradication with bismuth quadruple therapy: A systematic review and meta-analysis.","volume":"66","author":"Yu-Hao","year":"2025","journal-title":"Intern. J. Antimicrob. Agents"},{"key":"B109","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/apt.14561","article-title":"Systematic review with meta-analysis: The worldwide prevalence of Helicobacter pylori infection.","volume":"47","author":"Zamani","year":"2018","journal-title":"Alimentary Pharmacol. Therapeut."},{"key":"B110","doi-asserted-by":"publisher","first-page":"e67121","DOI":"10.1590\/fst.67121","article-title":"Application of minocycline in patients with Helicobacter pylori infection allergic to penicillin.","volume":"42","author":"Zhang","year":"2021","journal-title":"Food Sci. Technol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1016\/j.clinre.2017.04.004","article-title":"Probiotics in Helicobacter pylori eradication therapy: A systematic review and meta-analysis.","volume":"21","author":"Zhang","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"17562848241309870","DOI":"10.1177\/17562848241309870","article-title":"Ten-day vonoprazan-amoxicillin dual therapy versus 14-day esomeprazole-amoxicillin dual therapy for first-line Helicobacter pylori eradication: A prospective multicenter randomized controlled trial.","volume":"17","author":"Zhou","year":"2024","journal-title":"Therap. Adv. Gastroenterol."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1652943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:40:03Z","timestamp":1764744003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1652943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":112,"alternative-id":["10.3389\/fmicb.2025.1652943"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2025.1652943","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"article-number":"1652943"}}